Shopping Cart
- Remove All
- Your shopping cart is currently empty
KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 52 € | Backorder | |
5 mg | 231 € | Backorder | |
10 mg | 406 € | Backorder | |
25 mg | 892 € | Backorder |
Description | KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114. |
Alias | Ac-rRrGrKkRrSHWX1X2DI-OH (X1=tert-Leucine; X2=Cyclohexylglycine) |
Molecular Weight | 2201.60 |
Formula | C96H165N39O21.XCF3COOH |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: 1 mg/ml PBS pH 7.2: 10 mg/ml DMF: 1 mg/ml |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.